ERBB2 and breast cancer: Specifically, Sahlberg and colleagues proved that silencing either STARD3, GRB7, PSMD3, PERLD1, PPP1R1B, THRA, or GSDMA partially sensitized specific breast cancer cell lines to anti-HER2 agents [48].